Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PIMTREA vs ALYACEN 7/7/7
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PIMTREA is a small molecule inhibitor of the interaction between the PD-1 receptor and its ligands PD-L1 and PD-L2, acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Non-small cell lung cancer (NSCLC) with high PD-L1 expression (Trial 1),Advanced or metastatic NSCLC after prior chemotherapy (Trial 2)
Prevention of pregnancy
Intravenous 1000 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day cycle.
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
Terminal elimination half-life of 2.5 to 4 hours; prolonged in renal impairment (up to 6–12 hours in severe impairment).
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (Cr Cl 30-50 m L/min).
Primarily metabolized by CYP3A4 and CYP2D6; minor contributions from CYP2C9 and CYP2C19.
Norethindrone: primarily hepatic via reduction and conjugation, with CYP3A4 involvement. Ethinyl estradiol: primarily via CYP3A4, also undergoes sulfation and glucuronidation.
Primarily renal (approximately 70% as unchanged drug), with biliary/fecal excretion accounting for the remainder. Less than 5% metabolized.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Approximately 20% bound to plasma proteins (albumin).
98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein.
0.3–0.4 L/kg; indicates distribution primarily into extracellular fluid.
0.35 L/kg (total body water distribution); in obesity, Vd increases to 0.5 L/kg due to lipophilicity.
Oral: 30–40% due to incomplete absorption and first-pass metabolism.
Oral: 85% (with high-fat meal reduces to 70%); Sublingual: 90%.
For GFR 30-59 m L/min: reduce to 750 mg/m2; for GFR 15-29 m L/min: reduce to 500 mg/m2; for GFR <15 m L/min or dialysis: not recommended.
Contraindicated in patients with severe renal impairment (Cr Cl <30 m L/min) or acute renal failure due to drospirenone's antimineralocorticoid activity. No dose adjustment recommended for mild to moderate impairment (Cr Cl ≥30 m L/min).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: avoid use due to lack of data.
Contraindicated in patients with acute hepatic disease, hepatic tumors, or impaired liver function (Child-Pugh class B or C). Discontinue if jaundice or pruritus develops. No dose adjustment for Child-Pugh class A.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Not indicated for use in pediatric patients before menarche. Safety and efficacy in postmenarchal adolescents are expected to be similar to adults; dose is same as adults.
No specific dose adjustment based solely on age; monitor renal function and adjust accordingly.
Not indicated for use in postmenopausal women. No recommendations for geriatric population due to lack of indication.
Immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, and nephritis, can be severe or fatal. Monitor for signs and symptoms. Withhold or permanently discontinue based on severity.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives (COCs). Risk increases with age and amount smoked (especially >15 cigarettes/day). Women over 35 who smoke should not use COCs.
Risk of immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, and infusion-related reactions. Evaluate liver and renal function, thyroid function, and pregnancy status before initiation.
Thrombotic disorders (thrombophlebitis, pulmonary embolism, cerebral hemorrhage, myocardial infarction),Cerebrovascular disease,Carcinoma of the breast or reproductive organs,Hepatic adenoma or carcinoma,Ocular lesions (retinal thrombosis, papilledema),Gallbladder disease,Carbohydrate/lipid effects,Elevated blood pressure,Hereditary angioedema,Chloasma,Hepatic impairment
None known.
Breast cancer (current or history),Undiagnosed abnormal genital bleeding,Known or suspected pregnancy,Current or history of thrombotic disorders (DVT, PE, stroke, MI),Cerebrovascular or coronary artery disease,Valvular heart disease with complications,Severe hypertension,Diabetes with vascular disease,Headaches with focal neurological symptoms (e.g., migraine with aura),Major surgery with prolonged immobilization,Known thrombophilia (e.g., Factor V Leiden, prothrombin mutation, protein S/C deficiency),Active liver disease (tumors, hepatitis, cirrhosis),Uncontrolled hypertension,Smoking (if age >35),Hypersensitivity to any component
No specific food interactions. Grapefruit juice may slightly increase estrogen exposure but not clinically significant. Avoid St. John's Wort as it reduces efficacy.
Grapefruit and grapefruit juice may increase ethinyl estradiol levels, potentially increasing side effects. St. John's wort (herbal supplement) can reduce contraceptive efficacy. No other significant food interactions; however, maintaining a stable intake of vitamin C and folate is generally recommended.
Pimtrea (ethinyl estradiol and drospirenone) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects from population-based cohort studies, but data are limited. Second and third trimester exposure: may increase risk of fetal harm, including cardiovascular and genitourinary anomalies, due to hormonal effects. Use only if clearly needed after weighing risks; discontinue if pregnancy occurs.
ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does not warrant termination. Second and third trimesters: Avoid use due to potential adverse effects on fetal development, including feminization of male fetuses and potential for congenital anomalies from progestin. Postnatal: Possible long-term effects on reproductive development.
Ethinyl estradiol and drospirenone are excreted in human milk in small amounts; estimated M/P ratio for drospirenone is approximately 0.37. Combination hormonal contraceptives may reduce milk production and quality. Not recommended during lactation, especially in the first 6 months postpartum. Use alternative contraception.
Contraindicated in breastfeeding. Ethinylestradiol reduces milk quantity and quality. Norethindrone is excreted in low amounts (M/P ratio approximately 0.3-0.4). However, combination oral contraceptives are not recommended during lactation due to estrogen effects on milk production.
Pimtrea is contraindicated during pregnancy; no dosing adjustments applicable. Pharmacokinetic changes during pregnancy (e.g., increased hepatic metabolism, volume of distribution) may reduce efficacy; however, use is not recommended. If inadvertently exposed, discontinue drug.
ALYACEN 7/7/7 is contraindicated in pregnancy; no dose adjustments are applicable as use is not recommended. Pharmacokinetic changes in pregnancy (increased clearance of steroids) would theoretically require higher doses, but due to fetal risks, alternative therapies should be used.
Pimtrea (desogestrel/ethinyl estradiol) is a monophasic combined oral contraceptive. Counsel patients that missed pills increase pregnancy risk. Use with caution in smokers over 35 due to thromboembolism risk. Consider ARB/ACEI interaction for blood pressure control. No need for routine monitoring if asymptomatic.
ALYACEN 7/7/7 is a triphasic oral contraceptive containing ethinyl estradiol and norgestimate. The 7/7/7 regimen refers to the varying doses of norgestimate across three 7-day phases (0.18 mg, 0.215 mg, 0.25 mg) with a fixed 0.025 mg ethinyl estradiol. Use consistent 7-day placebo interval. Consider increased risk of venous thromboembolism (VTE) in patients with BMI >30, smoking >15 cigarettes/day, or age >35. Monitor for breakthrough bleeding, especially during the first 3 cycles. Avoid in patients with migraine with aura, uncontrolled hypertension, or history of DVT/PE. Drug interactions with CYP3A4 inducers (e.g., rifampin, carbamazepine) may reduce efficacy; consider backup contraception.
Take one pill daily at the same time; if missed, refer to package insert for instructions.,Do not smoke while taking this pill, especially if over 35.,Report sudden severe headache, chest pain, leg pain, or vision changes.,May cause nausea, breast tenderness, or breakthrough bleeding initially.,Protection against pregnancy starts after 7 consecutive days of correct use.
Take one pill daily at the same time each day, in the order specified on the pack (active pills followed by placebo).,If you miss a pill, follow the package instructions; missing pills increases pregnancy risk, especially if placebo week is extended.,Common side effects include nausea, headache, breast tenderness, and spotting, which usually improve after 2-3 cycles.,Seek immediate medical attention for severe abdominal pain, chest pain, shortness of breath, leg pain/swelling, or severe headache.,This medication does not protect against HIV/AIDS or other sexually transmitted infections (STIs).,Inform your healthcare provider if you smoke, as smoking increases risk of serious cardiovascular side effects, especially if over 35 years.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PIMTREA vs ALYACEN 7/7/7, answered by our medical review team.
PIMTREA is a Oral Contraceptive that works by PIMTREA is a small molecule inhibitor of the interaction between the PD-1 receptor and its ligands PD-L1 and PD-L2, acting as an immune checkpoint inhibitor to restore anti-tumor T-cell activity.. ALYACEN 7/7/7 is a Oral Contraceptive that works by Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PIMTREA and ALYACEN 7/7/7 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PIMTREA is: Intravenous 1000 mg/m2 over 10 minutes on days 1, 8, and 15 of a 28-day cycle.. The standard adult dose of ALYACEN 7/7/7 is: ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PIMTREA and ALYACEN 7/7/7 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PIMTREA is classified as Category C. Pimtrea (ethinyl estradiol and drospirenone) is contraindicated in pregnancy. First trimester exposure: no increased risk of major birth defects from population-based cohort studie. ALYACEN 7/7/7 is classified as Category C. ALYACEN 7/7/7 contains ethinylestradiol and norethindrone. First trimester: No increased risk of major birth defects based on epidemiologic studies; however, inadvertent use does n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.